Arabic Arabic English English French French German German
dark

Already on Fast Track, Aceragen Launches with $35 Million and Farber Disease Drug

Grabbing a fast-tracked novel enzyme replacement therapy for a rare pediatric disease, new biopharma Aceragen launched with $35 million in hand for product financing.   Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

A comprehensive review of the antiviral potential of algal metabolites.

Next Post

Study Investigates the Ability of Masimo PVi® to Predict Preload Responsiveness in Patients On Nasal High-Flow Therapy

Related Posts
Total
0
Share